IP Library Patent Application 18013047
Patent Application
App. No. 18/013,047

Improved Export of Oligosaccharides From Bacterial Cells

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/013,047
Abstract

Disclosed are genetically-engineered gram-negative bacterial cells for the production of an oligosaccharide of interest, wherein the bacterial cell possesses a saccharide transporter and/or a porin being expressed from a recombinant gene or a deregulated endogenous gene, thereby facilitating the translocation of the oligosaccharide of interest from the cell's cytoplasm into the cell's environment. Also disclosed are methods for producing an oligosaccharide of interest which used said genetically-engineered gram-negative bacterial cells.

Claims (23)

1 . A genetically-engineered gram-negative bacterial cell for the production of an oligosaccharide of interest, wherein the bacterial cell

possesses a cytoplasm, an inner membrane, an outer membrane and a periplasmic space between the inner membrane and the outer membrane,

is able to synthesize the oligosaccharide of interest intracellularly,

possesses

(i) a saccharide transporter in its inner membrane for the translocation of the oligosaccharide of interest from the cytoplasm across the inner membrane into the periplasmic space, and/or

(ii) a porin in its outer membrane for the translocation of the oligosaccharide of interest from the periplasmic space across the outer membrane,

wherein the saccharide transporter and/or the porin is expressed from a recombinant gene or a deregulated endogenous gene.

2 . The genetically-engineered bacterial cell according to claim 1 , wherein the oligosaccharide of interest is a human milk oligosaccharide.

3 . The genetically-engineered bacterial cell according to claim 2 , wherein the human milk oligosaccharide is selected from the group consisting of neutral HMOs and sialylated HMOs, preferably from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, 2′,3-difucosyllactose, lacto-N-triose II, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-neofucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-neofucopentaose V, lacto-N-difucohexaose I, lacto-N-difucohexaose II, 3′-galactosyllactose, 6′-galactosyllactose, lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose, para-lacto-N-neohexaose, difucosyl-lacto-N-neohexaose, 3′-sialyllactose, 6′-sialyllactose, lacto-N-sialylpentaose a, lacto-N-sialylpentaose b, lacto-N-sialylpentaose c, fucosyllacto-N-sialylpentaose a, fucosyl-lacto-N-sialylpentaose b, fucosyl-lacto-N-sialylpentaose c, disialyl-lacto-N-tetraose, disialyl-lacto-N-fucopentaose, disialyl-lacto-N-fucopentaose, 3-fucosyl-3′-sialyllactose, 3-fucosyl-6′-sialyllactose and lacto-N-neodifucohexaose I.

4 . The genetically-engineered bacterial cell according any one of the preceding claims, wherein the saccharide transporter is an endogenous transporter or a non-endogenous transporter, and/or wherein the porin is an endogenous porin or a non-endogenous porin.

5 . The genetically engineered bacterial cell according to claim 4 , wherein the bacterial cell has been genetically-engineered to overexpress the endogenous saccharide transporter and/or the endogenous porin.

6 . The genetically engineered bacterial cell according to claim 4 , wherein the bacterial cell has been genetically-engineered to express the non-endogenous saccharide transporter and/or the non-endogenous porin.

7 . Use a gram-negative bacterial cell according to any one of claims 1 to 6 for the production of an oligosaccharide of interest.

8 . A method for producing an oligosaccharide of interest, the method comprising the steps of

a) providing a genetically engineered gram-negative bacterial cell wherein the bacterial cell

possesses a cytoplasm, an inner membrane, an outer membrane and a periplasmic space between the inner membrane and the outer membrane,

is able to synthesize the oligosaccharide of interest intracellularly,

possesses (i) a saccharide transporter in its inner membrane for the translocation of the oligosaccharide of interest from the cytoplasm across the inner membrane into the periplasmic space, and

(ii) a porin in its outer membrane for the translocation of the oligosaccharide of interest from the periplasmic space across the outer membrane,

wherein the saccharide transporter and/or the porin is expressed from a recombinant gene

b) culturing the bacterial cell at conditions permissive for the bacterial cell to synthesize the oligosaccharide of interest intracellularly; and

c) retrieving the oligosaccharide of interest from the culture medium.

9 . A method for enhancing the export of an oligosaccharide of interest from a gram-negative bacterial cell into a culture medium said bacterial cell is cultured in, wherein the bacterial cell has been genetically engineered to synthesize the oligosaccharide of interest intracellularly, the method comprising the step of expressing a non-endogenous saccharide transporter and/or a non-endogenous porin from a recombinant gene in said bacterial cell, and/or by deregulating the expression of an endogenous saccharide transporter and/or an endogenous porin gene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2023
From: ENGLERT, MARKUS; JENNEWEIN, STEFAN; FRERIGMANN, HENNING; PARSCHAT, KATJA; TRÖTSCHEL, CHRISTIAN
To: CHR. HANSEN HMO GMBH
Reel/Frame 064399/0468 →